Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin for 12 Weeks in Subjects with Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Galaxy Study

We can cure hepatitis C virus after transplant, but what is the best regimen?

“…The vast majority of patients were HCV genotype 1, though a small number of patients with genotypes 2, 3, 4, and 6 were included. Consistent with the previously published clinical trials and real‐world and compassionate cohorts, the overall SVR12 rate was 96%.…”

“…The currently available DAA regimens that have included transplant recipients in published prospective trials include sofosbuvir/ledipasvir with ribavirin for 12 or 24 weeks, daclatasvir with sofosbuvir and ribavirin for 12 weeks, simeprevir with sofosbuvir and ribavirin for 12 weeks, and paritaprevir/ritonavir/ombitasvir with dasabuvir and ribavirin for 24 weeks, all enrolling almost exclusively HCV genotypes 1 and 4 . Overall response rates have been excellent, with 90%‐100% of patients achieving sustained virological response at 12 weeks (SVR12), including patients with early stage disease through compensated recurrent cirrhosis.…”

Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation

“…We all agree that the “new era” of antiviral therapy associated with the recent approval of highly effective and well‐tolerated regimens of direct‐acting antiviral agents (DAAs) has revolutionized the approach to the burden of HCV after LT , and several prospective trials have already been published on this topic . These trials were relatively small, however, and—given concerns about the impact of immunosuppression on response rates—patients were treated with RBV‐containing regimens, most of them for as long as 24 weeks.…”